Medivation upgraded to Buy at Roth Capital

Roth Capital upgraded Medivation (NASDAQ: MDVN) from “hold” to “buy.” The upgrade was based on a 65% probability of the FDA approving Medivation's Alzheimer treatment, Dimebon. Roth Capital has set the target price for MDVN at $34 and has recommended purchase of MDVN shares before the company releases its Phase 3 Dimebon data in 1H10.